Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561186 | 1.00 | PIN1 (0.47) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL28360178 | 0.85 | POLB (0.47) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6779283 | 0.84 | PIN1 (0.49) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL27540519 | 0.84 | PIN1 (0.49) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL9369385 | 0.83 | PIN1 (0.47) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL15991494 | 0.80 | EDNRB (0.46) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL28101975 | 0.80 | EDNRB (0.46) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL10983101 | 0.75 | CHRM2 (0.43) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8624932 | 0.75 | PIN1 (0.41) | PIN1MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6730801 | 0.75 | LMNA (0.43) | MEN1KMT2AALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248775-B1 | METHOD FOR THE ENANTIOSELECTIVE PREPARATION OF 3,3-DIPHENYL-2,3-EPOXY PROPIONIC ACID ESTERS | ABBOTT GMBH & CO KG (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-6677465-B2 | DIHYDROXYLATION OF 3-PHENYL CINNAMATE BY OSMIUM (VIII) OXIDE CATALYSIS IN PRESENCE OF SHARPLESS LIGAND AND OXIDIZING AGENT, SELECTIVE CONVERSION OF HYDROXY IN 2 POSITION TO LEAVING GROUP, INTRAMOLECULAR SUBSTITUTION TO FORM GLYCIDE ESTER | ABBOTT GMBH & CO. KG (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20030162982-A1 | Method for the enantioselective preparation of 3,3-diphenyl-2,3-epoxy propionic acid esters | ROYALTY PHARMA COLLECTION TRUST | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162982-A1 | Method for the enantioselective preparation of 3,3-diphenyl-2,3-epoxy propionic acid esters | ALDH3A1, HAO2, ERGIC1 | PIN1 688/4885MEN1 4626/4885KMT2A 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.